UCB (OTCMKTS:UCBJF) Shares Gap Down – Time to Sell?

UCB SA (OTCMKTS:UCBJF)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $302.16, but opened at $283.31. UCB shares last traded at $283.31, with a volume of 4 shares trading hands.

Analyst Upgrades and Downgrades

UCBJF has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of UCB in a research report on Monday, October 6th. Morgan Stanley reaffirmed an “overweight” rating on shares of UCB in a research note on Monday, September 8th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy”.

UCB Price Performance

The company’s 50-day moving average price is $255.69 and its 200-day moving average price is $207.98. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.